We are live on ! Find out more
Citadel Advisors

Citadel Advisors Portfolio holdings

AUM $618B
1-Year Est. Return 30.34%
 

Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.

This Fund
S&P 500
This Quarter Est. Return
+22.33%
1 Year Est. Return
+30.34%
3 Year Est. Return
+94.87%
5 Year Est. Return
+105.94%
10 Year Est. Return
+433.28%
AUM
$385B
AUM Growth
+$32.1B
Cap. Flow
-$35.1B
Cap. Flow %
-9.14%
Top 10 Hldgs %
30.5%
Holding
11,975
New
1,989
Increased
4,461
Reduced
4,218
Closed
1,130

Sector Composition

Rank Sector Weight
1 Technology 3.66%
2 Healthcare 3.16%
3 Industrials 2.01%
4 Financials 1.98%
5 Consumer Discretionary 1.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LCTX icon
10426
CALL
Lineage Cell Therapeutics
LCTX
$277M
$51K ﹤0.01%
+28,700
New +$40.1K
REFR icon
10427
CALL
Research Frontiers
REFR
$15.8M
$51K ﹤0.01%
18,000
-22,800
-56% -$64.3K
SENS icon
10428
CALL
Senseonics Holdings Inc
SENS
$273M
$51K ﹤0.01%
2,900
-655
-18% -$5.7K
TENX icon
10429
Tenax Therapeutics
TENX
$536M
$51K ﹤0.01%
+17
New +$31.3K
LMNL
10430
DELISTED
Liminal BioSciences Inc. Common Shares
LMNL
$51K ﹤0.01%
+1,220
New +$66.8K
ATOS icon
10431
CALL
Atossa Therapeutics
ATOS
$21.6M
$50K ﹤0.01%
3,493
+1,833
+110% +$42.4K
TWI icon
10432
PUT
Titan International
TWI
$466M
$50K ﹤0.01%
+10,200
New +$41.8K
MITO
10433
DELISTED
Stealth BioTherapeutics Corp. ADS
MITO
$50K ﹤0.01%
33,635
+21,446
+176% +$30.1K
SRAX
10434
CALL
DELISTED
SRAX, Inc. Class A Common Stock
SRAX
$50K ﹤0.01%
+16,000
New +$42.6K
ACR
10435
PUT
ACRES Commercial Realty
ACR
$112M
$49K ﹤0.01%
4,067
-1,833
-31% -$16.4K
APM
10436
DELISTED
Aptorum Group
APM
$49K ﹤0.01%
+2,002
New +$49.3K
MRKR icon
10437
CALL
Marker Therapeutics
MRKR
$20.3M
$49K ﹤0.01%
3,360
+600
+22% +$9.31K
SBBP
10438
CALL
DELISTED
Strongbridge Biopharma plc.
SBBP
$49K ﹤0.01%
20,100
+2,800
+16% +$6.75K
BBAR icon
10439
PUT
BBVA Argentina
BBAR
$3.86B
$48K ﹤0.01%
15,100
-2,300
-13% -$6.82K
BKD icon
10440
PUT
Brookdale Senior Living
BKD
$3.43B
$48K ﹤0.01%
10,800
-3,600
-25% -$13.3K
DRRX
10441
PUT
DELISTED
DURECT Corp
DRRX
$48K ﹤0.01%
2,300
-480
-17% -$9.13K
GSM icon
10442
FerroAtlántica
GSM
$607M
$48K ﹤0.01%
+29,477
New +$31K
LYG icon
10443
PUT
Lloyds Banking Group
LYG
$90.9B
$48K ﹤0.01%
+24,700
New +$41.6K
NERV icon
10444
Minerva Neurosciences
NERV
$185M
$48K ﹤0.01%
2,585
-2,614
-50% -$65.8K
JF
10445
J and Friends Holdings
JF
$17.4M
$48K ﹤0.01%
9,891
+3,173
+47% +$15.4K
GTT
10446
PUT
DELISTED
GTT Communications, Inc.
GTT
$48K ﹤0.01%
13,500
-10,700
-44% -$46.2K
ACR
10447
CALL
ACRES Commercial Realty
ACR
$112M
$47K ﹤0.01%
+3,933
New +$35.2K
FPAY
10448
DELISTED
FlexShopper
FPAY
$47K ﹤0.01%
+18,184
New +$35.1K
MNDO icon
10449
Mind CTI
MNDO
$20.6M
$47K ﹤0.01%
+18,003
New +$43.4K
QNTM
10450
Quantum Biopharma Class B Subordinate Voting Shares
QNTM
$19.5M
$47K ﹤0.01%
+465
New +$54.9K

Similar funds

Citadel Advisors's Q4 2020 Portfolio in Review

As of Q4 2020, Citadel Advisors held 11,975 positions worth $385B, up 9.1% from $353B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Citadel Advisors withdrew a net $35.1B in Q4 2020, closing 1,130 positions and reducing 4,218 holdings. Its most notable exit was Immunomedics Inc, an estimated $213M position sold in full.

By sector, the portfolio is most concentrated in Technology at 3.7% of assets, up from 3% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, Citadel Advisors opened a new position in S&P Global worth $114M.

  • Citadel Advisors's largest Q4 2020 buy was S&P Global: 345,785 shares worth $114M.
  • Citadel Advisors added most to iShares Core S&P 500 ETF in Q4 2020, an estimated $1.16B increase.
  • Citadel Advisors's biggest Q4 2020 reduction was Amazon, cutting an estimated $1.55B.
  • Citadel Advisors fully exited Immunomedics Inc in Q4 2020, selling an estimated $213M.
  • Citadel Advisors's ten largest holdings make up 31% of its $385B portfolio in Q4 2020.
  • Citadel Advisors opened 1,989 new positions and closed 1,130 in Q4 2020.
  • Citadel Advisors's portfolio value rose 9.1% quarter-over-quarter to $385B.

Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.